Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Systemic Scleroderma: early-phase trial registry
2 of 5 indexed Systemic Scleroderma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Systemic Scleroderma: 5 US clinical trials tracked, 2 recruiting.
Systemic Scleroderma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Boston University, running 2 of these trials.
Enrollment posture brief
Registry condition systemic-scleroderma
OPEN 2 | RECR 40% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Systemic Scleroderma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Systemic Scleroderma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Systemic Scleroderma is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Systemic Scleroderma research.
Boston University accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Systemic Scleroderma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Systemic Scleroderma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
Boston University
NCT07090226
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
City of Hope Medical Center
NCT04380831
Longitudinal Spatial Frequency Domain Imaging Study
Boston University
NCT05672992
CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study
George Washington University
NCT00522002
Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
Northwestern University
NCT00278525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Systemic Scleroderma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Systemic Scleroderma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Systemic Scleroderma page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Systemic Scleroderma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Boston University sponsors the most Systemic Scleroderma trials on record, review their full trial history before evaluating a specific study. See Boston University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Systemic Scleroderma condition card totals 5 registered trials; most-linked intervention Spatial-frequency domain imaging (SFDI); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.